Impact of treatment with bevacizumab beyond disease progression: a randomized phase II study of docetaxel with or without bevacizumab after platinum-based chemotherapy plus bevacizumab in patients with advanced nonsquamous non-small cell lung cancer Full Text
BMC Cancer, 08/08/2012
Takeda M et al. – Patients in arm A will receive docetaxel at 60mg/m2 and those in arm B will receive docetaxel at 60mg/m2 plus bevacizumab at 15mg/kg, with each drug administered on day 1 every 21 days until progression or unacceptable toxicity. The primary endpoint of the study is progression–free survival, with secondary endpoints including response rate, overall survival, and safety, for patients treated in either arm.